AWM
TOVX icon

Apollon Wealth Management’s Theriva Biologics TOVX Stock Holding History

Apollon Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed – – 634
2020
Q2 		$0 Buy
+1
New +$95 ﹤0.01% 757

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Apollon Wealth Management's TOVX Position: Q3 2020 in Review

Apollon Wealth Management sold out of Theriva Biologics (TOVX) in Q3 2020, closing a stake of 1 share.

Apollon Wealth Management first reported a position in TOVX in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 14 funds tracked by Wall St. Rank hold TOVX as of Q3 2020.

  • Apollon Wealth Management reported no remaining Theriva Biologics position as of Q3 2020 after selling out during the quarter.
  • Apollon Wealth Management sold 1 Theriva Biologics share in Q3 2020.
  • Apollon Wealth Management first reported a position in Theriva Biologics in Q2 2020 and held it in 1 quarter.
  • Apollon Wealth Management's Theriva Biologics position peaked at $0 in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2020.

Based on Apollon Wealth Management's 13F filing for Q3 2020, filed 3 Nov 2020.